Clinical Trials Browser

Adrenocortical Carcinoma

Sinonasal Squamous Cell Carcinoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Basal Cell, Skin Neoplasms

Carcinoma, Renal Cell

HPV-Related Squamous Cell Carcinoma

Carcinoma, Renal Cell

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Squamous Cell Carcinoma of Head and Neck

Solid Tumors

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Neoplasm Metastasis

SMARCB1-Deficient Malignancies

Uveal Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Colonic Neoplasms

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Adrenocortical Carcinoma

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

Urinary Bladder Neoplasms

Adenocarcinoma, Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Melanoma

Natural Killer/T-cell Lymphoma

Clinical Trials

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

I-SPY

CEMI-first

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

MINIMA

LAG-BOOST

GAP Cemi

N-PLANC

ICARS

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

SPORADIC

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

THIO Sequenced With Cemiplimab in Advanced NSCLC

SWITCH

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

PALACE

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

INTERVAL

VIRO-25

TRIPL

NeoSTOP-IT

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

ICING